Overview:

Summary

Pharmaceutical and healthcare report,” Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016” provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-label formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapies

Scope

The scope of the report includes:

• Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.

• Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

• Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.

• Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos Biotechnology AG and Ono Pharmaceutical Co. Ltd.

• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

• The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future allergic conjunctivitis market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market.

• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global allergic conjunctivitis market in future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

• What’s the next big thing in the global allergic conjunctivitis market landscape? - Identify, understand and capitalize.

Companies Mentioned

Novagali Pharma S.A
Fovea Pharmaceuticals SA
Cytos Biotechnology AG
Ono Pharmaceutical Co. Ltd

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Allergic Conjunctivitis Market : Market Characterization

2.1 Disease Overview

2.2 Symptoms

2.3 Treatment

2.3.1 Allergic Conjunctivitis - Major Different Classes of Drug Description

2.4 Allergic Conjunctivitis Market Size

2.5 Allergic Conjunctivitis Market Forecast and CAGR

2.6 Drivers and Barriers for the Allergic Conjunctivitis Market

2.6.1 Drivers for the Allergic Conjunctivitis Market

2.6.2 Barriers for the Allergic Conjunctivitis Market

2.7 Opportunity and Unmet Need

2.8 Key Takeaway

3 Allergic Conjunctivitis Market : Competitive Assessment

3.1 Overview

3.2 Strategic Competitor Assessment

3.3 Product Profiles of the Major Marketed Products in the Allergic Conjunctivitis Market

3.3.1 Bepreve (bepotastine besilate ophthalmic solution) 1.5%

3.3.2 Patanol / Opatanol (olopatadine hydrochloride ophthalmic solution) 0.1%

3.3.3 Elestat (epinastine HCl ophthalmic solution) 0.05%

3.3.4 Alomide (lodoxamide tromethamine) ophthalmic solution 0.1%

3.4 Key Takeaway

4 Allergic Conjunctivitis Market : Pipeline Assessment

4.1 Overview

4.2 Strategic Pipeline Assessment

4.2.1 Technology Trends Analytic Framework

4.3 Allergic Conjunctivitis Therapeutics - Promising Drugs under Clinical Development

4.4 Molecule Profile for Promising Drugs under Clinical Development

4.4.1 Vekacia (cyclosporine A)

4.4.2 FOV1101 (Prednisporin)

4.4.3 ONO-6126

4.5 Allergic Conjunctivitis Market - Clinical Pipeline by Mechanism of Action

4.6 Allergic Conjunctivitis - Pipeline by Clinical Phases of Development

4.6.1 Allergic Conjunctivitis Therapeutics - Phase III Clinical Pipeline

4.6.2 Allergic Conjunctivitis Therapeutics - Phase II Clinical Pipeline

4.6.3 Allergic Conjunctivitis Therapeutics - Phase I Clinical Pipeline

4.6.4 Allergic Conjunctivitis Therapeutics - Preclinical Pipeline

4.7 Key Takeaway

5 Allergic Conjunctivitis Market : Implications for Future Market Competition

6 Allergic Conjunctivitis Market : Future Players in the Allergic Conjunctivitis Market

6.1 Introduction

6.2 Novagali Pharma S.A

6.2.1 Company Overview

6.2.2 Ophthalmic Portfolio

6.2.3 Allergic Conjunctivitis Product Portfolio

6.3 Fovea Pharmaceuticals SA

6.3.1 Company Overview

6.3.2 Ophthalmic Portfolio

6.3.3 Allergic Conjunctivitis Product Portfolio

6.4 Cytos Biotechnology AG

6.4.1 Company Overview

6.4.2 Financial Performance

6.4.3 Business Description

6.4.4 Ophthalmic Portfolio

6.4.5 Allergic Conjunctivitis Product Portfolio

6.5 Ono Pharmaceutical Co. Ltd

6.5.1 Company Overview

6.5.2 Financial Performance

6.5.3 Business Description

6.5.4 Ophthalmic Portfolio

6.5.5 Allergic Conjunctivitis Product Portfolio

 

7 Allergic Conjunctivitis Market : Appendix

7.1 Market Definitions

7.2 Abbreviations

7.3 Research Methodology

7.3.1 Coverage

7.3.2 Secondary Research

7.3.3 Forecasting

7.3.4 Primary Research

7.3.5 Expert Panels

7.4 Contact Us

7.5 Disclaimer

7.6 Sources

1.1 List of Tables

Table 1: Global Allergic Conjunctivitis Therapeutics Market, Revenue ($m), 2001-2009

Table 2: Global Allergic Conjunctivitis Therapeutics Market, Revenue ($m), 2009-2016

Table 3: Marketed Products Analysis in Allergic Conjunctivitis Market, 2010

Table 4: Allergic Conjunctivitis Therapeutics - Most Promising Drugs under Clinical Development, 2010

Table 5: Allergic Conjunctivitis Therapeutics - Phase III Clinical Pipeline, 2010

Table 6: Allergic Conjunctivitis Therapeutics - Phase II Clinical Pipeline, 2010

Table 7: Allergic Conjunctivitis Therapeutics - Phase I Clinical Pipeline, 2010

Table 8: Allergic Conjunctivitis Therapeutics - Preclinical Pipeline, 2010

Table 9: Novagali Pharma S.A - Marketed Products, 2010

Table 10: Novagali Pharma S.A - Pipeline Products, 2010

Table 11: Fovea Pharmaceuticals SA - Pipeline Products, 2010

Table 12: Cytos Biotechnology AG - Pipeline Products, 2010

Table 13: Ono Pharmaceutical Co. Ltd- Pipeline Products, 2010

1.2 List of Figures

Figure 1: Global Allergic Conjunctivitis Therapeutics Market, Revenue ($m), 2001-2009

Figure 2: Global Allergic Conjunctivitis Therapeutics Market, Revenue ($m), 2009-2016

Figure 3: Opportunity and Unmet Need in the Allergic Conjunctivitis Market, 2010

Figure 4: Strategic Competitor Assessment of the Marketed Products for Allergic Conjunctivitis, 2010

Figure 5: Technology Trends Analytic Framework of the Allergic Conjunctivitis Pipeline, 2010

Figure 6: Technology Trends Analytic Framework of the Allergic Conjunctivitis Pipeline - Description, 2010

Figure 7: Allergic Conjunctivitis Market - Clinical Pipeline by Mechanism of Action, 2010

Figure 8: Allergic Conjunctivitis Pipeline by Phase of Clinical Development, 2010

Figure 9: Implications for Future Market Competition in the Allergic Conjunctivitis Market, 2010

Figure 10: Allergic Conjunctivitis Market - Clinical Pipeline by Company, 2010

Figure 11: GlobalData Methodology

Figure 12: GlobalData Market Forecasting Model